GlassScriptPhysician profile
Jordan Johnson
NPI 1194207662
$2,431.81
in general payments reported to CMS, 2019-2025
21 companies · $494 in 2025
The $494 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.79 · 2020: $33.97 · 2021: $22.31 · 2022: $407 · 2023: $708 · 2024: $700 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $760.07 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Alcon Vision LLC | $239.22 | 2022-2025 | Precision7, Clareon, Rhopressa |
| Coopervision INC. | $181.25 | 2024-2025 | Myday Contact Lens |
| Horizon Therapeutics Plc | $154.26 | 2022-2023 | Tepezza |
| Dompe US, INC. | $151.09 | 2022-2024 | Oxervate |
| Glaukos Corporation | $149.53 | 2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Ani Pharmaceuticals, INC. | $148.93 | 2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $148.62 | 2020-2023 | |
| Oyster Point Pharma, INC. | $146.34 | 2022-2023 | Tyrvaya |
| Amgen INC. | $60.40 | 2024 | Tepezza |
| Allergan, INC. | $50.00 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $40.86 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $36.11 | 2023-2024 | Tecnis Iol |
| Astellas Pharma US INC | $23.91 | 2023 | |
| Sun Pharmaceutical Industries INC. | $23.76 | 2023 | Cequa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $23.30 | 2024 | Xdemvy |
| Thea Pharma INC. | $23.21 | 2024 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $22.31 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.79 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.29 | 2020 | |
| Abbvie INC. | $15.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.